A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.
Meropenem has been studied across 8 research domains including 🫘 Kidney, 🧠 Focus & Attention, 🫁 Liver & Detox, ✨ Skin & Hair, 🫁 Respiratory. The primary research focus is 🫘 Kidney with 12% of studies addressing this area.
The following compounds share molecular targets with Meropenem, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Meropenem is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.